Skip to main content
FinSpry Logo
FinSpry
BMRN logo
BMRN
(NASDAQ)
BioMarin Pharmaceutical Inc.
$56.77-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

BioMarin Pharmaceutical (BMRN) Stock Price & Financial Analysis

BioMarin Pharmaceutical Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$56.09 - $57.71
52-Week High$66.28
52-Week Low$49.26
Open$56.09
Volume2.23M
Average Volume (3M)2.29M
Market Cap11.16B
Shares Outstanding197.67M
P/E Ratio (TTM)41.54
Forward P/E80.73
Price to Sales (P/S)3.44
Price to Book (P/B)1.80
EV/EBITDA23.99
Revenue (TTM)3.24B
Net Income (TTM)268.74M
Free Cash Flow (TTM)759.12M
EPS (TTM)$1.37
Profit Margin8.29%
Operating Margin13.55%
Return on Equity (ROE)4.33%
Debt to Equity0.23
50-Day MA$54.27
200-Day MA$55.77
52-Week Change2.71%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About BioMarin Pharmaceutical

What is the current stock price for BMRN?

As of the latest trading session, BMRN stock trades at $56.77. The 52-week range is $49.26–$66.28, with a day range of $56.09–$57.71.

What is the P/E ratio for BMRN?

BioMarin Pharmaceutical's trailing P/E ratio is 41.5, meaning investors pay $41.5 for every $1 of annual earnings. The forward P/E is 80.7, reflecting analyst expectations for future earnings. BioMarin Pharmaceutical operates in the Healthcare sector.

Does BMRN pay dividends?

BioMarin Pharmaceutical does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for BMRN?

Based on 1 analyst, the consensus for BMRN is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of BMRN?

BioMarin Pharmaceutical's market capitalization is $11.22B, classifying it as a large-cap company. BioMarin Pharmaceutical operates in the Healthcare sector within the Biotechnology industry.